How big is ZimVie, Inc.?

As of Jun 18, ZimVie, Inc. has a market capitalization of 244.31 million, with net sales of 443.55 million and a net profit of -24.89 million over the latest four quarters.

Market Cap: As of Jun 18, ZimVie, Inc. has a market capitalization of 244.31 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ZimVie, Inc. reported net sales of 443.55 million and a net profit of -24.89 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 381.71 million and total assets of 753.67 million.

What does ZimVie, Inc. do?

ZimVie, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $112 million and a net loss of $3 million as of March 2025. It has a market cap of $244.31 million and key metrics indicating a loss-making status with no dividend yield.

Overview:<BR>ZimVie, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 112 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 244.31 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.40 <BR>Return on Equity: -1.76% <BR>Price to Book: 0.62 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold ZimVie, Inc.?

Is ZimVie, Inc. overvalued or undervalued?

As of August 10, 2022, ZimVie, Inc. is considered risky and overvalued with a Price to Book Value of 0.66 and an EV to EBITDA of 11.89, despite a strong year-to-date return of 35.48%, which lags behind the S&P 500's three-year performance.

As of 10 August 2022, the valuation grade for ZimVie, Inc. moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 0.66, an EV to EBITDA of 11.89, and an EV to Sales ratio of 0.95, which suggest that the stock may not justify its price given its financial performance.<BR><BR>In comparison to its peers, ZimVie, Inc. has a notably high EV to EBIT ratio of 419.62, while AngioDynamics, Inc. has a significantly lower EV to EBITDA of 226.06, highlighting a stark contrast in valuation. Additionally, the company's recent stock performance shows a year-to-date return of 35.48%, which outperforms the S&P 500's 12.22% return, but its longer-term performance over three years (42.32% vs. 70.41%) indicates that it has lagged behind the benchmark.

Is ZimVie, Inc. technically bullish or bearish?

As of October 10, 2025, ZimVie, Inc. shows a bullish trend supported by positive MACD and Bollinger Bands, despite a bearish weekly RSI and mixed KST signals, with a year-to-date return of 35.99% significantly outperforming the S&P 500's 11.41%.

As of 10 October 2025, the technical trend for ZimVie, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Additionally, the Bollinger Bands are bullish on both time frames, and the daily moving averages are also bullish. However, the weekly RSI is bearish, indicating some short-term weakness. The KST shows a bullish weekly signal but is bearish monthly, and the OBV is mildly bullish weekly with no trend monthly. <BR><BR>In terms of performance, ZimVie has outperformed the S&P 500 significantly, with a year-to-date return of 35.99% compared to the S&P 500's 11.41%, and a 3-year return of 147.01% versus 81.39% for the index. Overall, the current stance is bullish, driven by strong MACD and Bollinger Band signals, despite some mixed indicators in the RSI and KST.